Proactive therapy: New perspectives for long-term topical treatment of psoriasis

被引：4

作者：

Lis-Swiety, Anna ^{[1
]}

Fratczak, Aleksandra ^{[1
]}

机构：

[1] Med Univ Silesia, Fac Med Sci Katowice, Dept Dermatol, Katowice, Poland

来源：

DERMATOLOGIC THERAPY | 2022年 / 35卷 / 05期

关键词：

outcome; psoriasis; topical therapy; DIPROPIONATE FOAM; EFFICACY; SAFETY; CALCIPOTRIOL; MANAGEMENT; FORMULATION; 52-WEEK; GEL;

D O I：

10.1111/dth.15364

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Mild to moderate psoriasis is most often treated with topical therapy. The article reviews literature on topical treatments that have been assessed in clinical trials and real-life studies lasting at least 12 months. Calcipotriol/bethamethasone dipropionate foam in maintenance treatment following the induction phase can improve efficacy and safety of topical therapy in psoriatic patients. Introduction of new topical nonsteroidal drugs and the wider use of proactive therapy seem to be crucial to achieve satisfactory long-term outcomes in psoriasis.

引用

页数：4

共 17 条

[1] Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice [J].

Augustin, Matthias ;

Mrowietz, Ulrich ;

Bonnekoh, Bernd ;

Rosenbach, Thomas ;

Thaci, Diamant ;

Reusch, Michael ;

Ardabili, Michael ;

Reich, Kristian .

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 (08) :667-682

[2] Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis [J].

Fenix, Kevin ;

Wijesundara, Danushka K. ;

Cowin, Allison J. ;

Grubor-Bauk, Branka ;

Kopecki, Zlatko .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) :1-13

[3] Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland [J].

Harvima, Rauno J. ;

Gooderham, Melinda ;

Tyring, Stephen ;

Thoning, Henrik ;

Nyholm, Nanna ;

Stein Gold, Linda .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) :2234-2240

[4] Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis [J].

Ito, Kotaro ;

Koga, Monji ;

Shibayama, Yoshitsugu ;

Tatematsu, Saori ;

Nakayama, Juichiro ;

Imafuku, Shinichi .

JOURNAL OF DERMATOLOGY, 2016, 43 (04) :402-405

[5] Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG [J].

Jalili, A. ;

Calzavara-Pinton, P. ;

Kircik, L. ;

Lons-Danic, D. ;

Pink, A. ;

Tyring, S. ;

de la Cueva, P. ;

Gooderham, M. ;

Segaert, S. ;

Nyholm, N. ;

Thoning, H. ;

Petersen, B. ;

Thaci, D. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (01) :60-67

[6] Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®/Dovobet®/Taclonex®) in the treatment of psoriasis vulgaris [J].

Kragballe, K. ;

Austad, J. ;

Barnes, L. ;

Bibby, A. ;

de la Brassinne, M. ;

Cambazard, F. ;

Fleming, C. ;

Heikkila, H. ;

Williams, Z. ;

Rey, J. Peyri ;

Svensson, A. ;

Toole, J. ;

Wozel, G. .

DERMATOLOGY, 2006, 213 (04) :319-326

[7] A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris [J].

Kragballe, K. ;

Austad, J. ;

Barnes, L. ;

Bibby, A. ;

de la Brassinne, M. ;

Cambazard, F. ;

Fleming, C. ;

Heikkila, H. ;

Jolliffe, D. ;

Peyri, J. ;

Svensson, A. ;

Toole, J. ;

Wozel, G. .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (06) :1155-1160

[8] Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study [J].

Lambert, J. ;

Hol, C. W. ;

Vink, J. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (12) :2349-2355

[9]

Lebwohl M, 2021, J AM ACAD DERMATOL, V84, P1269, DOI 10.1016/j.jaad.2020.09.037

[10] Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis [J].

Lebwohl, Mark G. ;

Sugarman, Jeffrey L. ;

Gold, Linda Stein ;

Pariser, David M. ;

Lin, Tina ;

Pillai, Radhakrishnan ;

Martin, Gina ;

Harris, Susan ;

Israel, Robert .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) :282-285

← 1 2 →